|
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Both hepatic PCK1 and plasma FGF21 correlated strongly and inversely with hepatic TG content, suggesting a key role for PCK1 and increased gluconeogenesis in resolving steatosis with a high-protein diet, with FGF21 expression reflecting declining cell stress.
|
28457799 |
2017 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
A Novel Role of SIRT1/ FGF-21 in Taurine Protection Against Cafeteria Diet-Induced Steatohepatitis in Rats.
|
28942443 |
2017 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGF21 depletion exacerbated alcohol-induced hepatic steatosis and liver injury, which was associated with increased activation of genes involved in lipogenesis mediated by SREBP1c and decreased expression of genes involved in fatty acid β-oxidation mediated by PGC1α. rhFGF21 administration reduced alcohol-induced hepatic steatosis and inflammation in WT mice.
|
27498701 |
2016 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Equally, repressed expression of the B-lymphocyte chemoattractant CXCL13 and STAT4 as well as induced FGF21 evidenced amelioration of steatosis-related inflammation.
|
27376874 |
2016 |
|
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Forced FGF21 expression in partial hepatectomized hPPARα(PAC) reduced hepatic steatosis, prevented focal necrosis, and restored liver mass.
|
25991671 |
2015 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
APS treatment suppressed abnormal glycolipid metabolism and insulin resistance following 8 weeks of catch‑up growth by improving hepatic SIRT1‑PPARα‑FGF21 intracellular signaling and reducing chronic inflammation, and by partially attenuating hepatic steatosis.
|
26323321 |
2015 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGF21 KO mice were subjected to chronic-binge alcohol exposure, and epididymal white adipose tissue lipolysis and liver steatosis were investigated.
|
26092866 |
2015 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The administration of FGF21 reverses hepatic steatosis, counteracts obesity and alleviates insulin resistance in rodents and nonhuman primates.
|
25516477 |
2015 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Administration of recombinant FGF21 in mice alleviated tunicamycin-induced liver steatosis, in parallel with reduced eIF2α-ATF4-CHOP signaling.
|
25170079 |
2014 |
|
Steatohepatitis
|
0.400 |
Therapeutic
|
disease |
CTD_human |
SIRT1-mediated activation of FGF21 prevents liver steatosis caused by fasting.
|
24184811 |
2014 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGF21 is a promising intervention therapy for metabolic diseases as fatty liver, obesity and diabetes.
|
23590285 |
2013 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Liver X receptor negatively regulates fibroblast growth factor 21 in the fatty liver induced by cholesterol-enriched diet.
|
21889884 |
2012 |
|
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In human liver tissues, FGF21 mRNA expression increased with the degree of steatosis.
|
20675007 |
2010 |